← All trials
NCT05404724
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2022
- Primary completion
- Jul 11, 2022
- Completion date
- Jul 11, 2022
- First posted
- Jun 3, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 14
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.